Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM. Such preventative therapies might be administered either short term (during the time around the period otherwise known as the peri-menstrual period or PMP) or continuously throughout the menstrual cycle.
Frovatriptan has been developed for the management of migraine and is already licensed for use as an acute treatment for this condition. Previous well controlled clinical trials have highlighted the potential of frovatriptan as a short-term preventative medication for MM. This clinical trial was meant to further explore this indication for frovatriptan in an expanded population.
See above
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Frovatriptan 2.5mg QD | Drug | |||
| Frovatriptan 2.5 mg BID | Drug | |||
| placebo | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Primary endpoint Number of MRM headache free PMPs out of a potential of three treated PMPs |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of MRM headache | ||
| Maximum headache intensity | ||
| Incidence of moderate or severe MRM headaches |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C108128 | frovatriptan |
| C494814 | BID protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Number of MRM headache free days during treated PMPs |
| Incidence of MRM headache associated symptoms (e.g. photophobia, phonophobia, nausea and vomiting) |
| Functional impairment during treatment phase |
| Time to onset (days) of MRM headache (during the treated PMP and until five days post treatment) |
| Time to onset of first post-treatment migraine Incidence of intercurrent migraine outside of the peri-menstrual period Use of rescue medication |
| D009422 | Nervous System Diseases |